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  PRL-3 is a multi-tasking phosphatase involved in cancer metastasis.  It promotes various 
cancer-related properties, such as motility, invasiveness and tumorigenicity.  Two important 
features of cancer progression are Epithelial-Mesenchymal Transition (EMT) and evasion of 
programmed cell death.  EMT is a process that is important for embryonic development and 
oncogenesis.  This process causes epithelial cells to adopt a migratory mesenchymal phenotype.  
Evasion of apoptosis allows transformed cells to survive in the circulation to reach distant 
secondary sites.  Here we attempt to understand the role of PRL-3 in these two processes.  In this 
study, we found that cells expressing PRL-3 exhibited reduced focal adhesion proteins paxillin, 
phosphorylated paxillin-Tyr31 and vinculin.  Additionally, there was reduction in RhoA-GTP, 
Racl-GTP and filamentous-actin (F-actin).  DLD-1 human colorectal cancer cells stably 
expressing EGFP-PRL-3 showed activation of Akt by PRL-3 and inactivation of glycogen 
synthase kinase-3β.  In these cells, PRL-3 also down-regulated epithelial markers E-cadherin, γ-
catenin (plakoglobin) and integrin β3 while up-regulating mesenchymal markers fibronectin and 
snail.  These changes could all be abrogated by the phophoinositide 3-kinase (PI3K) inhibitor 
LY294002.  Thus PRL-3 would act upstream of PI3K to initiate EMT during cancer metastasis.  
PRL-3 also down-regulates phosphatase and tensin homologue deleted on chromosome 10 
(PTEN), which is a key antagonist of PI3K, reinforcing PI3K/Akt activation.   These changes 
point to PRL-3 promoting EMT by signalling through PI3K and down-regulating PTEN.   
Activation of Akt is also known to have effects on cell cycle regulation and cell survival.  We 
found that MCF7 cells and DLD-1 cells stably expressing EGFP-PRL-3 were more resistant to 
genotoxic agents methyl methanesulfonate (MMS) and doxorubicin, as well as oxidative stress 
induced by H2O2.  We screened protein lysates from these cells using a commercial antibody 
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array to find cell cycle related proteins whose phosphorylation status could be modified by PRL-
3, and for proteins that could interact with PRL-3.  We identified the Growth Arrest and DNA 
Damage protein GADD34 as a candidate that fulfils both conditions consistently across different 
cell lines.  To understand how PRL-3 could mediate GADD34 phosphorylation, we looked for 
changes in Lyn, a Src family kinase known to phosphorylated GADD34 and negatively regulate 
its pro-apoptotic response to genotoxic apoptosis.  Surprisingly, we found that PRL-3 down-
regulated Lyn protein as well as mRNA.  We take this finding to indicate that PRL-3 might 
promote phosphorylation of GADD34 by an alternative pathway that is independent of Lyn.  
These events require PRL-3 phosphatase activity, as the catalytically inactive mutant PRL-3 
(C104S) could not effect these changes.  We propose that PRL-3 confers resistance to apoptosis 
through phosphorylation and inhibition of GADD34.  These findings are part of the growing 
body of evidence that PRL-3 is a multi-tasking phosphatase involved in cancer metastasis 











Chapter 1. Introduction 
1.1 Cancer Progression and Metastasis 
Cancer research in the past quarter century has revealed this complex disease to be a multistep 
process, in which cells acquire traits that allow them to override normal cell proliferation and 
homeostasis regulation to progress from normalcy to malignancy.  The physiological changes in 
tumorigenesis can be classified into six broad categories:  self sufficiency in growth signals, 
insensitivity to growth-inhibitory (anti-growth) signals, limitless replicative potential, sustained 
angiogenesis, and tissue invasion and metastasis [1].  These traits are acquired through genetic 
and epigenetic changes in the cancer cells and further supported by normal neighbouring cells in 
the tumour microenvironment. 
    Approximately 90% of cancer deaths are due to metastatic lesions rather than primary 
tumours.  The classical overview of metastasis consists of several steps – local invasion, 
intravasation, survival in the circulation, extravasation and colonization [2].   Each of these steps 
requires the cells to overcome barriers of physiological checks and balances that maintain 
healthy tissue function.   Such barriers that suppress tumour formation include extracellular 
matrix components, basements membranes, reactive oxygen species, the limited availability of 
nutrients and oxygen, and attack by the immune system [3].  These factors exert selective 
pressure that promotes outgrowth of cells that are able to adapt and thrive in microenvironments 
that would be inhospitable to normal cells. 
    Cell-cell adhesion and attachment to the extracellular matrix regulate signals for cell growth 
and proliferation.  Altered cell adhesion liberates cells from the normal constraints of tissue 
architecture [3].  Cell surface receptors are important transducers of growth-stimulatory signals, 
and their deregulation is associated with tumour pathogenesis. For example, members of the 
ErbB family of Receptor Tyrosine Kinases (RTKs) are deregulated in non-small-cell lung 
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cancer, among others [4].  Integrins, which are extracellular matrix receptors, modulate cell-cell 
attachments, polarity, survival and proliferation through the ERK/MAPK and PI3K/Akt 
pathways [5].   E-cadherin is a well studied epithelial cell marker, and is a component of cell-cell 
adherens junctions.  The transcriptional repression or functional loss of E-cadherin is associated 
with progression to tumour malignancy [6] and is a hallmark of Epithelial-Mesenchymal 
Transition (EMT) [7].   Cells with altered adhesion thus become more motile, enabling them to 
depart from the primary tumour mass. 
  Adhesion plays a central role in cell survival.  Anchorage independence is another important 
characteristic of malignant cells that allows them to survive and proliferate in suspension without 
need of attachment to the extracellular matrix (ECM) and other cells.  As these cells acquire 
more aberrations to their genes and enter the circulatory system, they need to overcome cell 
cycle arrest and evade apoptosis, or programmed cell death.  Apoptosis is an important process 
in development, homeostasis and in controlling cell numbers in adult multi-cellular organisms.  
Disruption of the balance between cell multiplication and cell death can lead to malignancy [8, 
9].  Apoptosis is mediated by a number of molecular pathways that result in the activation of 
endonucleases, DNA fragmentation and cell death.  Anoikis, a subset of apoptosis, is induced 
when cells do not interact appropriately with the ECM to prevent detached cells from attaching 
to new matrices [10]. Integrins are the sensors of cell matrix anchorage and transmit adhesion 
dependent signals through focal adhesion kinase (FAK), integrin-linked kinase (ILK) and Rho 
GTPases.  These signal transduction pathways converge to the activation of PKB/Akt, which in 
its activated form suppresses pro-apoptotic proteins such as Bad, pro-caspase 9 and DAP-3, and 
stimulates survival proteins [11].   Apoptosis is also triggered by DNA damage and genomic 
instability.  These injuries are detected by the ATM (ataxia telangiectasia Rad3 related) family of 
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DNA damage sensors to key effectors such as p53, E2F-1 and c-Abl [12].  Corruption of the 
apoptotic machinery allows cells with altered adhesion and aberrant genomes to survive and 
proliferate. 
  Tumour growth and metastasis require nutrients to be supplied to the cells in order for the 
tumour mass to expand.   Angiogenesis is the process by which neovasculature sprouts from 
existing blood vessels and tumour cells are able activate the “angiogenic switch” to induce 
surrounding endothelial cells to build neo-vasculature to supply blood to support the growth of 
the tumour cells [13].  These new vessels creates a route by which the cells have access to the 
circulatory system and are thus able to travel to other organs in the body.  This is known as 
intravasation.  Tumour cells can also gain access to the lymphatic system through a similar 
process of lymphangiogenesis [3, 14].  When the cells reach an appropriate tissue, they 
extravagate (exit the circulation) and arrive in a secondary site.   
  Two models of understanding cancer progression have been proposed by Christoph Klein.  The 
first linear progression model describes malignant potential as being acquired in the primary 
tumour before metastatic dissemination of fully malignant cells.  In the second parallel 
progression model, tumour cells migrate from the primary site before progressing to full 
malignancy at a distant site [15].  The choice of organ where the secondary metastasis establishes 
itself depends on the origin of the primary tumour cells, the path the cells take through the blood 
and lymph circulation and on a viable microenvironment of the secondary tissue.  Disseminated 
tumour cells might remain dormant in new sites for a period of time.  They can exist in the form 
of preangiogenic metastases where cells are proliferating, but overall growth is kept in check by 
the rate of apoptosis.  In mice, dormant lung metastases were found to exhibit rapid growth when 
inhibition of angiogenesis was removed [16].  Thus, the ability to become vascularised is a factor 
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in determining the emergence of these cells from dormancy.  Solitary tumour cells can also exist 
in a quiescent state of cell cycle arrest.  These cells can be induced out of quiescence when 
introduced to a compatible microenvironment.  Solitary mouse mammary carcinoma cells that 
were dormant in the liver were shown to retain tumourigenic potential when re-injected into 
mammary fat pads of mice [17].  Paget’s seed and soil hypothesis suggests that cancer cells 
“seed” needs  permissive “soil” of an appropriate organ to grow [18]. This hypothesis explains 
why certain types of tumours show organ-specific patterns of metastasis, for example breast 
cancer metastasizes to bone, liver, brain and lungs while colorectal cancer develops metastases in 
the liver.  As the tumour cells exit dormancy to active proliferation, the preangiogenic 
micrometastases develop vasculature the supports formation of macroscopic tumours. 
 
1.2 Protein Phosphorylation 
  Protein phosphorylation regulates signalling pathways that influence cellular processes such as 
metabolism, transcription, cell-cycle progression, differentiation, cytoskeleton arrangement, cell 
movement and apoptosis.  The enzymes that regulate phosphorylation and dephosphorylation are 
protein kinases and protein phosphatases respectively.  Protein kinases mediate phosphorylation 
of either serine and threonine residues or tyrosine residues.  Protein kinases catalyse the transfer 
of the terminal phosphate group of an ATP molecule to the hydroxyl group on a serine, threonine 
or tyrosine side chain of the target protein.  The phosphate group carries a double negative 
charge and causes a conformational change in the protein structure by allowing interaction of the 
phosphorylated residue with positively charged residues, such as arginine [19].  This 
conformational change can either activate or inhibit enzyme activity.  The attached phosphate 
group can also form part of the structure of a recognition site for other proteins with 
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phosphotyrosine-binding domains.  Thus protein phosphorylation drives the assembly and 
disassembly of protein complexes [20].  In humans, out of 6000 phosphorylation sites identified 
in 2000 proteins, the proportion of serine, threonine and tyrosine phosphorylation sites is 86.4, 
11.8 and 1.8% respectively [21].  Despite the lower frequency of occurrence, tyrosine 
phosphorylation is critically important in mitogenic signalling and cancer biology.  Tyrosine 
phosphorylation is thought to have evolved later than serine/threonine phosphorylation, as they 
are found in multicellular organisms but lacking in unicellular organisms [19].   
  Protein Tyrosine Kinases (PTKs) are classified as receptor or non-receptor tyrosine kinases.  
Many signalling ligands act through cell-surface RTKs.  Ligand binding to RTKs leads to 
autophosphorylation to activate the kinase and create docking sites for phosphorylation-
dependent protein interaction domains.  For example, docking of epidermal growth factor (EGF) 
to EGF Receptor (EGFR) leads to dimerisation of the receptors and autophosphorylation of 
several tyrosine residues Y1068, Y1148 and Y1173 [22].  These phosphorylated tyrosines act as 
docking sites for proteins with SH2 (Src homology 2) or PTB (phosphotyrosine-binding) 
domains.  This association activates various downstream signaling pathways, such as MAPK, 
Akt and JNK (c-Jun N-terminal kinase) pathways.  Non-receptor tyrosine kinases include the Src 
family of protein tyrosine kinases (SFKs).  This family of tyrosine kinases couples receptors to 
cytoplasmic signal effectors [23].  Many SFKs are oncogenes due to their role in regulating 
cellular proliferation.  The family of SFKs include Src, Fyn, Yes, Hck, Blk, Fgr, Lyn and Yrk.  
SFKs regulate cell adhesion, motility and apoptosis through key molecules in integrin-mediated 
signalling pathways such as FAK, paxillin and p130CAS [24].  Src is mainly activated by the 
dephosphorylation of negative regulatory tyrosine 527.  Increased Src activity has been found in 
mammary, colon and pancreatic cancer.  Src directly interacts with integrins and is required for 
8 
 
normal adhesion and focal adhesion turnover.  Phosphatidylinositol 3-kinase (PI3K) belongs to a 
unique family of kinases that phosphorylate phosphoinositide lipids.  PI3K phosphorylates and 
converts phosphatidylinositol (4,5) bisphosphate (PIP2) to phosphtidylinositol (3,4,5) 
triphosphate (PIP3). PIP3 then recruites phosphatidylinositol-dependent kinase 1 (PDK1) and 
PKB/Akt to the membrane by binding their pleckstrin homology (PH) domains, allowing PDK1 
to phosphorylate and activate Akt.  The PKB/Akt pathway is a critical pathway that contributes 
to cellular processes such as cell survival, growth, proliferation, angiogenesis, metabolism and 
migration [25]. 
  Cellular protein phosphorylation is modulated by the coordinated activities of protein kinases 
and protein phosphatases. Protein phosphatases can be classified as Protein Ser/Thr Phosphatases 
and Protein Tyrosine phosphatases (PTPs).  Initially, it was thought that PTPs played 
housekeeping roles, and functioned promiscuously to reverse phosphorylation by RTKs.  It is 
now known that they have specific targets and physiological functions.  As with PTKs, 
deregulation of PTP activity also contributes to pathogenesis of human diseases.  The PTP 
superfamily can be further subcategorised into classical Tyr specific PTPs, dual specificity 
phosphatases (DSPs), Cdc25 phosphatases and low molecular weight (LMW) PTPs [26].  PTPs 
are carry a conserved catalytic domain of ~240 residues with the signature motif 
[I/V]HCxAGxxR[S/T]G [27].  The catalytic reaction that PTPs involves nucleophilic attack of 
the phosphorus atom of the substrate by the sulphur atom of the thiolate ion of the essential 
cysteine residue, resulting in transfer of the phosphate group to the enzyme, forming a 
phophoryl-cysteine intermediate.  The dephosphorylated product is released when the conserved 
aspartic acid near the active site cleft protonates the leaving group phenolic oxygen by acting as 
a general acid.  The phosphoenzyme intermediate is then hydrolysed by water and the phosphate 
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is transferred to an acceptor to regenerate the PTP [28, 29]. Mutants of the Cys to Ser or Ala are 
catalytically inactive and mutants of Asp to Ala are substrate trapping mutants that retain the 
ability to bind substrates but also have lowered catalytic function [30].  The substrates of the PTP 
family include proteins, phosphoinositides and mRNAs. 
The tumour suppressor PTEN (Phosphatase and tensin homolog deleted from chromosome 10) is 
a dual specificity lipid phosphatase that negatively regulates PI3K signalling by 
dephophorylating the D3-inositol position of PIP3, converting it back to PIP2.  PTEN is one of 
the most frequently mutated tumour suppressor genes in human cancer.  One of the main 
functions of PTEN is in apoptosis and cell cycle control.  Loss of PTEN function results in 
accumulation of PIP3 at the membrane and hyperactivation of Akt.  Activated Akt signalling 
results in attenuated response to apoptotic stimuli, as Akt prevents release of cytochrome c from 
the mitochondria, inactivates Forkhead transcription factors involved in expressing key apoptosis 
genes, and inactivates proapoptotic Bad and caspase-9.  Conversely, over-expression of PTEN 
results in inactivation of Akt and the induction of apoptosis initiated by loss of contact from the 
extracellular matrix (anoikis).  PTEN is also involved in FAK and Shc phosphorylation in 
response to integrin signalling, thus regulating signals for cell adhesion and migration [31].  
PTEN loss also compromises genomic integrity because of altered DNA damage response [32]. 
1.3 PRL family of Protein Tyrosine Phosphatases 
  The Phosphatase of Regenerating Liver (PRL) family of protein tyrosine phosphatases 
comprises of three members:  PRL-1, PRL-2 and PRL-3.  The first member, PRL-1 was 
identified as an immediate-early gene in rat regenerating liver after partial hepatectomy (referred 
to as SL-314 in reference 33) [33].  The PRL-1 sequence was found to contain the signature 
sequence for a protein tyrosine phosphatase (PTPase), VHCXAGXXR.  Diamond et al observed 
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that PRL-1 is highly expressed in growing hepatic cells and some tumour cell lines, and 
modulates cell growth [34]. PRL-1 and PRL-2 (also known as PTPCAAX1 /PTP4A1 and PTPCAAX2 
/PTP4A2 respectively) were found to contain the C-terminal consensus sequence CAAX motif 
for prenylation and were indeed prenylated, putting them in a novel class of prenylated non-
classical PTPs [35], where C is cysteine, A is an aliphatic residue, and X is any animo acid.  
PRL-2 and PRL-3 (also known as PTP4A3) were identified by Zeng et al using Expressed 
Sequence Tags (ESTs) database searches with rat PRL-1 amino acid sequence.  Mouse, rat and 
human PRL-1 are 100% identical.  Mouse and human PRL-2 are also 100% identical.  Mouse 
PRL-2 and PRL-3 are 87.4% and 75.7% identical to PRL-1 respectively.  Mouse PRL-2 is 75.4% 
identical to mouse PRL-3 [36].  The crystal structures of PRL-1 and PRL-3 place them in the 
family of DSPs, with closest homology to Cdc14 and PTEN.  They have shallow catalytic 
pockets that can accommodate a wide range of substrates [37, 38].   
  Studies of transcripts in human tissues show that PRL-1 and PRL-2 are expressed generally 
ubiquitously, with the exception of a few specialised tissues [39].  Transcripts of PRL-3, 
however, were found to be expressed mainly in heart and skeletal muscle [36].  In cells, the 
CAAX prenylation motif indicates that PRLs undergo this post-translational lipid modification to 
target the proteins to membranes, and they are typically associated with the plasma membrane 
and early endosome.  Prenylation is essential for PRL function.  In the absence of prenylation, 
PRLs localise in the cytoplasm and/or nucleus [40].  PRLs also contain a C-terminal polybasic 
region that allows PRL interaction with PI(3)P, PI(4)P and PI(5)P, indicating the PRLs might be 





1.4 PRL-3 and cancer metastasis 
The oncogenic role of PRLs was hinted at by their role in cell growth and their constitutive 
expression in tumourigenic H35 cells [34].  Cates et al also observed that over-expression of 
PRL-1 and PRL-2 in epithelial cells results in loss of contact inhibition and tumour formation in 
nude mice [35].  These were early indications of the oncogenic role of PRLs. Vogelstein’s group 
carried out a pivotal study that highlighted the role of PRL-3 in cancer progression and 
metastasis [43].  In this study, they carried out a global gene expression profile using SAGE 
(Serial Analysis of Gene Expression) technology.  They compared transcripts from liver 
metastases of colorectal cancer with primary cancers, benign colorectal tumours and normal 
colorectal epithelium.  144 transcripts were expressed at higher levels in metastatic colonic cells 
from the liver, compared to non-metastatic and normal colon epithelial cells.  Of these, only 
PRL-3 was found to consistently over-expressed in all the metastatic samples.  In the same 
paper, the correlation between PRL-3 expression and colorectal cancer progression could be 
observed, based on a study of matched samples from six patients.  PRL-3 was expressed at low 
levels in normal colorectal epithelium and benign adenomas, at intermediate levels in primary 
tumours and at high levels in the colorectal cancer liver metastases.    In situ hybridization and 
immunohistochemisty studies of primary colorectal cancer also show PRL-3 mRNA and protein 
to be elevated in 11-45% of colorectal cancer primary tumours and metastatic lesions to various 
organs [42, 44, 45].  Notably, high expression of PRL-3 was linked with venous invasion [44].  
PRL-3 expression level was found to have potential as a prognostic marker of development of 
liver and lung metastasis.  Out of 177 primary colorectal cancer tumours, 84.4% of cases with 
liver metastases had elevated levels of PRL-3 transcript compared to 35.9% of those without 
liver metastases.  88.9% of cases with lung metastases had elevated levels of PRL-3 transcript 
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compared to 42.3% of those without lung metastases [44].  High PRL-3 expression predicted 
reduced metastasis-free and overall survival after surgery [44, 46].   Enhanced PRL-3 expression 
has also been linked to cancer progression and metastasis in other organs.  Immunohistological 
detection revealed that high PRL-3 expression was found in ductal carcinomas in situ, and in 
invasive breast carcinoma [47].  Wang et al found 34.8% of 382 operable primary breast cancers 
expressed a high level of PRL-3 and that patients with PRL-3 positive tumours had a reduced 5-
year disease-specific survival (DSS) rate [48].  PRL-3 has also been studied in gastric 
carcinomas [49, 50].  In these studies, gastric carcinomas with nodal metastasis were found to 
have high PRL-3 transcript and protein levels more frequently than those without.  Northern blot 
analysis of 27 liver carcinomas and 5 normal liver samples showed up-regulation of PRL-3 
mRNA levels in almost all the carcinomas compared to normal tissues [51].  In non-small cell 
lung cancer however, PRL-3 transcripts were slightly decreased in primary tumours compared to 
matched normal tissue, but were greatly reduced in lung metastases, up to 10 times in some cases 
[52].  Zhou et al also linked PRL-3 to nasopharyngeal cancer (NPC) [53].  They found that PRL-
3 mRNA and protein was over-expressed in nasopharyngeal carcinoma cell lines and over-
expression of PRL-3 was linked to shortened overall survival for patients with nasopharyngeal 
cancer.  Thus PRL-3 is also a potential prognostic factor for progression of NPC.   
  With elevated PRL-3 levels being associated with the development and progression of such a 
broad range of human carcinomas, PRL-3 would be expected to have effects on cancer-related 
cell processes. Zeng et al studied some of these properties in Chinese Hamster Ovary (CHO) 
cells stably over-expressing Myc-tagged PRL-1 and PRL-3 [54].  The motility of these cells was 
studied with wound healing assays.  Compared to Myc-β-gal-transfected control cells, both Myc-
PRL-1 and PRL-3 expressing cells were found to have enhanced migration.  In transwell assays, 
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both also showed increased invasion as well as migration.  Injection of these cells into the tail 
veins of nude mice produced metastasis in lungs of all the mice, and liver metastasis in 2 out of 
10 mice injected with Myc-PRL-3 expressing cells.  Wu et al also studied the promotion of 
motility and metastasis in mouse melanoma cells by PRL-3 [51].  They used metastatic 
melanoma B16-BL6 cells that expressed a higher level of PRL-3 mRNA than their parental B16 
cell line.  When B16 cells were transfected with PRL-3, they were found to lose their epithelial 
cell morphology and adopted a more elongated mesenchymal fibroblast-like appearance.  Their 
migration and invasiveness became comparable to B16-BL6 cells.  This effect was dependent on 
phosphatase activity.  The expression of PRL-3 was also shown to increase adhesion to 
fibronectin and laminin, while decreasing adhesion to type I collagen.  Guo et al then showed 
that the phosphatase activity of PRL-3 is essential for its tumourigenic and metastatic effects 
[55].  CHO cells expressing EGFP-PRL-3 (C104S) phosphatase inactive mutant were compared 
with wild-type EGFP-PRL-3 expressing CHO cells.  While wild type PRL-3 expressing cells 
showed tumourigenicity in soft agar assay and when injected into the hips of nude mice, this 
effect was significantly reduced in C104S mutant PRL-3 expressing cells.  Tail vein injection of 
these cells also demonstrated that EGFP-PRL-3 (C104S) cells did not form lung metastasis, 
while wild type PRL-3 cells did.  Another finding in this paper was that upon examining serial 
lung sections with EGFP-PRL-3 tumours, the EGFP-PRL-3 tumours were observed to be 
established within blood vessels.  The tubular structures surrounding the EGFP-PRL-3 tumours 
were shown to be blood vessels by staining with the endothelial cells marker von Willebrand 
Factor (vWF) and histopathological investigation by Haematoxylin & Eosin staining. 
This observation of EGFP-PRL-3 tumours in blood vessels hinted at PRL-3’s possible role in 
tumour–related angiogenesis.  This prompted Guo et al to study how PRL-3 can affect 
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communication with endothelial cells [56].  They found through immunohistochemical analysis 
of human and rat tissue, that PRL-3 protein was expressed in foetal rat heart and premature small 
blood vessels but not in their mature counterparts.  Pre-erythrocytes were found to express PRL-
3 protein and mRNA, not megakaryocytes (mature red blood cells).  To study if PRL-3 
expressing cells could be involved in cross-talk to human umbilical vascular endothelial cells 
(HUVECs), they used an in vitro three dimensional coculture system.  HUVECs were grown 
with fibroblasts which were then overlaid with EGFP-PRL-3 expressing DLD-1 or CHO cells.  
Indirect immunofluorescence revealed that the PRL-3 expressing cells were able to recruit 
HUVECs to rearrange them into clusters that were well coordinated with the patches of PRL-3 
expressing cells.  CHO AT-3, a highly metastatic EGFP-PRL-3 expressing tumour-derived cell 
line, was also used together with CHO EGFP-PRL-3 (C104S) and EGFP-PRL-3 cells in an in 
vivo xenograft model.  The cells were mixed with Matrigel and injected into the hips of nude 
mice.  Tumours from nude mice injected with AT-3 cells were largest and most highly 
vascularised followed by those injected with EGFP-PRL-3 cells.  The underlying mechanism for 
this cross talk was investigated by screening 36 angiogenesis related cytokines in the cell culture 
media.  The expression of the cytokine IL-4 was found to be reduced by over-expression of PRL-
3.  Addition of IL-4 to the earlier in vitro coculture system indeed prevented cross talk between 
the PRL-3 expressing CHO cells and HUVECs.  Thus, attenuation of IL-4 expression is a likely 
mechanism by which PRL-3 can recruit endothelial cells to initiate angiogenesis. 
  Together, these studies have revealed that PRL-3 is up-regulated in a broad range of major 
cancers and is involved in their progression to metastasis.  PRL-3 has potential as a prognostic 
marker for disease progression and disease free survival in these cancers.   PRL-3 also affects a 
number of important cell processes involved in progression of cancer.  Transformed cell 
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morphology and altered cell adhesion are reminiscent of Epithelial Mesenchymal Transition, 
which enables cells to detach from their structured epithelial layers and become more migratory.  
Enhanced cell motility and invasiveness are traits that allow cancer cells to be more aggressive in 
reaching and entering new secondary sites.  Angiogenesis allows tumours to have access to the 
circulation and have a supply of nutrients to support their growth beyond the size of 
preangiogenic metastases, which depend on the diffusion of nutrients. Taken together, the over-
expression of PRL-3 can drive processes that factor throughout all the stages of metastasis, and 
its phophatase activity is essential for these effects. 
1.5 PRL-3 mediated cell signalling 
  To understand how PRL-3 brings about such changes in cell properties, its molecular 
mechanisms need to be investigated.  We found that PRL-3 down-regulates PTEN and promotes 
epithelial-mesenchymal transition (EMT) in a PI3K-dependent manner [57].  Key focal adhesion 
components were also found to be reduced.  The details of this work will be discussed in Chapter 
3.  Joint integrin/receptor tyrosine kinase (RTK) signalling controls cell adhesion to the 
extracellular matrix (ECM) and response to growth factors [58].  Integrins mainly signal through 
focal adhesion kinase (FAK), Src-family kinases (SFKs), Rho family GTPases and adaptor 
proteins paxillin and p130Cas [5].  Ligand binding to integrins results in recruitment of FAK, 
which activates PI3K/Akt signalling and recruits Src to focal adhesions.  Src phosphorylates 
p130Cas and paxillin to activate Rac downstream.  Deregulated activity of these components 
renders cancer cells independent of growth factors and ECM signals for proliferation, and 
insensitive to apoptotic stimuli.  Peng et al linked PRL-3 to integrin signalling when they 
identified integrin α1 as a PRL-3 binding protein in HEK293 cells [59].  They also found that the 
tyrosine phosphorylation of integrin β1 could be down-regulated by PRL-3, accompanied by 
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increased phosphorylation of Erk1/2.  Liang et al found that PRL-3 expression in HEK 293 cells 
led to down-regulation of C-terminal Src Kinase (Csk) resulting in increased Src activation by 
reduced inhibitory phosphorylation of Tyr527 [60].  Src activation led to an increase in tyrosine 
phosphorylation of Stat3, p130Cas and Erk1/2 [60].  The activation of these pathways promotes 
cell migration and proliferation. 
   The Rho family of small GTPases are key regulators of the actin cytoskeleton in cell motility, 
transcription and cell cycle progression.  Fiordalisi et al found that over-expression of PRL-3 and 
PRL-1 in SW480 cells resulted in increased levels of active RhoA and RhoC, while the activity 
of Rac was reduced and there was no effect on Cdc42 activity [61].  In the case of PRL-3, these 
effects were dependent on the phosphatase activity, as demonstrated by use of catalytically 
inactive mutants C104A and D72A. 
  Ezrin is a member of the ERM (Ezrin-Radixin-Moesin) family of proteins that coordinate 
membrane cytoskeletal reorganisation, cell shape determination, membrane transport and signal 
transduction [62].  Forte at al found that PRL-3 was able to dephosphorylate the Thr567 and 
tyrosine residues of Ezrin in HCT116 cells [63].  Phosphorylation activates Ezrin to bridge F-
actin to the cell membrane.  It is interesting to note that Ezrin function is controlled by Src 
phsosphorylation and affects cell adhesion in epithelial cells [64].  Ezrin can also be activated by 
Rho and inactivated by Rac [65]. 
  PRL-3 is known to be localised at the plasma membrane and early endosome, and seems to 
carry out its functions with its binding partners integrin α1 and ezrin at the plasma membrane.  
The activity of PRL-3 on Rho family GTPases is farnesylation dependent [61], thus suggesting 
membrane localisation dependence.  In the case of Csk and PTEN, which are negative regulators 
of their respective pathways, PRL-3 down-regulates both to cause an activation of the Src and 
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PI3K/Akt pathways respectively.  In both cases, the effects are relatively far upstream of the 
signalling pathways, which crosstalk in EMT and other cellular processes.  In summary, the 
molecular signalling of PRL-3 affects key components that control cell-cell adherens junctions, 
cell-ECM focal adhesion as well as cytoskeletal reorganisation.   
 
1.6 PRL-3 as a target for cancer therapy 
  The broad ranging expression of PRL-3 in colorectal, breast, ovarian, gastric and liver cancer, 
and its emergence as a key player in transformation and metastasis of cancer cells makes it a 
very attractive target for therapeutic intervention [66].  The fact that PRL-3 is over-expressed in 
metastasis makes it a more suitable target compared to tumour suppressor genes that are 
inactivated.  It is difficult to activate a gene that is switched off, but it is possible to inhibit or 
suppress excessive phosphatase activity. 
    Pathak et al. were able to inhibit all three PRLs with the drug pentamidine [67].  Pentamidine 
is an anti-protozoa drug in clinical use for treatment of leishmaniasis, Gambian trypanosomiasis 
and Pneumocystis carinii pneumonia.   Pentamidine at therapeutic doses was found to inhibit the 
phosphatase activity of recombinant PRL-1, -2 and -3 in vitro, as well as the growth of several 
PRL-3 transcript expressing cell lines in culture.  It also halted tumour progression in a WM9 
tumour human melanoma nude mouse xenograft.  However, pentamidine also inhibited other 
phosphatases like PTP1B and MKP1, so the therapeutic effects might also be due to inhibition of 
other phosphatases. 
  In 2006, two Korean groups identified compounds that were PRL-3 inhibitors.  Ahn et al. used 
high-throughput screening of a chemical library to screen for PRL-3 inhibitors and found 
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rhodanine to be a candidate [68].  They synthesised rhodanine derivatives and found one with a 
2-bromobenzyl substituent and one with a 2-chloro-6-fluorobenzyl substituent to be more 
effective in inhibiting PRL-3 than pentamidine.  They were also more effective in reducing the 
invasiveness of B16F10 cells in vitro.  Choi et al. screened plant extracts against PRL-3 and 
found the menthol extracts of young branches of Taxus cuspidae to have 80% PRL-3 inhibitory 
activity at 100μg/ml [69].  Fractionation of the extracts revealed two biflavinoid compounds 
ginketin and sciadopitysin with PRL-3 inhibitory properties.  These natural products might have 
less toxicity and side effects than synthetic chemicals. 
  Transfection of PRL-3 and PRL-1 specific small interfering RNA into DLD-1 cells was shown 
to reduce their motility (in vitro) and hepatic colonisation (in vivo) in mice.  However, their 
proliferation rates remained unaffected [44]. 
  The importance of PRL localisation to the membrane for its functions could also be exploited 
for therapeutic inhibition.  PRLs are farnesylated and their membrane association could be 
blocked by farnesyltransferase (FTase) inhibitors (FTIs) [40].  However treatment with FTIs 
would not target PRLs specifically and would affect other farnesylated proteins as well, 
potentiating side effects. 
Detecting expression of PRL proteins for diagnostic purposes requires specific antibodies which 
can distinguish between PRL-1, PRL-2 and PRL-3.   This is a challenging task because of the 
high degree of homology between the three members of the family.  PRL-3 is about 76% 
homologous to PRL-1 and PRL-2 [36].  In 2005 our group established two PRL-1-specific 
monoclonal antibodies (mAbs) (clones 269 and 29) and two PRL-3-specific monoclonal 
antibodies (clones 318 and 223) [45].  However, no PRL-2 specific antibody could be 
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established.  The PRL-1 and PRL-3 specific antibodies can be used for diagnostic, prognostic 
and therapeutic purposes. 
  Antibodies are useful for directed recognition of antigens to signal destruction of undesirable 
cells or pathogens by the immune system.  Our group used an in vivo animal model to form 
metastasis in nude mice, to show that PRL antibodies can be used to inhibit growth of tumours 
caused by injection of PRL over-expressing cells [70].  The mice were injected with EGFP-PRL-
1 or EGFP-PRL-3 over-expressing cells, and then subsequently treated with PRL-1 or PRL-3 
mAbs.  This treatment inhibited formation of EGFP-PRL-1 or PRL-3 metastatic lung tumours 
with 90% efficacy.  This effect was further shown to be due to the antibodies targeting their own 
specific antigen in the cells, and there was also no cross-reactivity between PRL-1 and PRL-3 
antibodies in this treatment. In this paper, it was also demonstrated that a portion of the PRL 
expressing cells could take up their respective antibodies even in unpermeabilized conditions. 
The use of antibodies for therapeutic treatment has traditionally been limited to targets located at 
the surface of cells.  However, PRL-3 is located on the inner surface of the cell membrane.  This 
study proposes the possibility of cancer therapy using antibodies to target PRLs and other 
intracellular oncoproteins to prevent progression of metastasis. 
1.7 Rationale of work 
  In order to metastasize, cancer cells become more motile and invasive.  They need to detach 
themselves from other cells in the epithelia and from the ECM in order to leave their site of 
origin and extravagate into the blood or lymphatic system.  This process is similar to the process 
of Epithelial-Mesenchymal Transition (EMT) that is important in normal embryonic 
development and wound healing.  This process is defined by certain molecular or morphological 
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features [71].  Epithelial cells are highly differentiated and have apical basal polarity.  They form 
well-organised epithelial sheets (epithelia) and adhere to one another through anchoring 
junctions that join their cytoskeletons to their neighbouring cells or the ECM.  These include gap 
junctions, tight junctions, desmosomes and adherens junctions.  In focal adhesions, integrins link 
actin filaments to allow the cells to attach to the ECM.  Adherens junctions connect the actin 
filaments of cells.  Cell migration and invasion is the result of the dynamic disassembly and 
reassembly of these adhesions, as well as the cytoskeleton itself and is subject to contact 
inhibition.  Mesenchymal cells form transient intracellular junctions and have an elongated 
morphology with leading/trailing edge asymmetry, with filopodia dynamically interacting with 
the extra cellular matrix.  Weakened cell adhesions are an important part of tumour invasiveness.  
This transformation allows cells to detach from their site of origin, and pass through blood vessel 
endothelia and enter blood circulation. 
  PRL-3 is a phosphatase that takes on multiple roles in metastasis, influencing key cellular 
processes in cancer progression.  However, its signalling pathways are not yet clearly 
established.  We previously showed that PRL-3 could promote motility, invasion and migration 
[54]. Wu et al. also found that mouse melanoma cells transfected with PRL-3 lost their epithelial 
morphology and became more mesenchymal and fibroblast-like in appearance [51]. 
  We aimed to study the ability of PRL-3 to promote EMT and uncover the molecular 
mechanisms through which PRL-3 might achieve this.  We used cells that over-expressed PRL-3 
and first looked for evidence of EMT by observing key molecules in focal adhesions and the 
cytoskeleton.  Reduced focal adhesions and destabilised cytoskeletons are an indication that 
EMT might be occurring.  To demonstrate this change in cell properties, we studied the protein 
levels of key epithelial and mesenchymal markers.  There are several molecules that are 
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important features of EMT and cell adhesions.  Paxillin is part of a complex of cytoskeletal 
proteins and binds to vinculin, a key focal adhesion protein [72].  Cell movement requires 
dynamic cytoskeletal rearrangement, in particular filamentous-actin (F-actin) [73].  E-cadherin is 
an adherens junction component that is an important marker of the epithelial cell type.  Loss of 
E-cadherin is associated with increased invasiveness. E-cadherin is part of a cadherin-catenin 
complex with γ-catenin (also known as plakoglobin).  This complex links to actin filaments [74].  
Integrins are important in attachment of cells to the ECM and transmitting mechanical and 
chemical signals from the ECM.  These cell surface proteins are key markers of the epithelial 
cell type and we here show that PRL-3 over-expression causes down-regulation of these markers.  
At the same time, mesenchymal cell type markers such as fibronectin and the transcription 
regulator Snail were up-regulated.  These are all hallmarks of EMT [73, 75].  
  The process of EMT is regulated by several signalling pathways.  Rho family GTPases are key 
regulators of cytoskeletal dynamics.  Their activation and localisation control actin 
polymerisation and front-back polarisation of the cell during migration [76].  Decreased RhoA 
activity might indicate decreased adherens junction stability.  Rac activity controls the actin 
polymerisation and stabilises microtubules.  PTEN and the PI3K/Akt pathway orchestrate 
signalling through GSK-3β to regulate Snail, a transcriptional suppressor of E-cadherin [77].  To 
determine if PRL-3’s involvement in Akt activation is dependent on PI3K, we used PI3K 
inhibitor LY294002 to treat the cells and observed if the effects we observed could be abrogated.  
We propose PRL-3 is able to act through multiple interconnected pathways to drive 
transformation of cells from an epithelial to mesenchymal phenotype. 
  Besides EMT, the PI3K/AKT pathway can regulate a variety of cellular processes.  Akt is 
involved in cell proliferation and cell cycle regulation through p27Kip1 and Chk1.  Akt also 
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regulates the stability and translation of proteins involved in cell cycle entry through GSK3, 
TSC2 and PRAS40.  Akt also promotes cell survival through negative regulation of proapoptotic 
proteins such as BAD and transcription factors such as FOXO and p53 [25].  PRL-3 was recently 
found to be a p53-inducible gene during DNA damage-induced cell cycle arrest [78, 79].  Basak 
et al. found that a basal level of PRL-3 is necessary for normal cell cycle progression and 
inhibition of over-expression of PRL- 3 could lead to p53-dependent cell cycle G1 arrest.  This 
cell cycle arrest was linked to inhibition of the PI3K/Akt pathway.  This was in contrast to 
previous findings that over-expression of PRL-1 and PRL-2 could enhance cell cycle 
progression, enhance cyclin-dependent kinase 2 (CDK2) activity and down-regulate p21Cip1/Waf1 
[80].   It is indeed paradoxical that PRL-3, a metastasis gene, would be induced by a tumour 
suppressor to bring about cell cycle arrest.  This startling finding indicates that there is a delicate 
balance in the homeostasis of PRL-3 signalling. 
  Programmed cell death and cell cycle arrest are important barriers to developing metastases.  
Deregulation of apoptosis leads to accumulation of “undead” cells that contributes to tumour 
development [8]. Integrin mediated attachment to the ECM activates pro-survival signals through 
Erk, JNK and Akt pathways.  Apoptosis can be triggered by loss of cell anchorage or 
inappropriate cell adhesion.  This is a defence to prevent detached cells reattaching to new 
matrices.  Failure to repair damaged DNA leads to genomic instability and apoptosis in normal 
cells. Failure to carry out apoptosis allows anchorage independent proliferation of “homeless” 
and transformed cells.  Apoptosis/anoikis is also a phenotypic marker of EMT [75]. 
  The balance between pro-apoptotic factors and pro-survival signals determines cell fate.  
Integrins are the sensors of cell-ECM attachment and signal multiple pathways to coordinate 
survival signals.  FAK becomes auto-phosphorylated upon integrin-mediated cell attachment and 
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activates PI3K and Akt, resulting in suppression of anoikis [81].  Activation of Akt was also 
reported to overcome G2/M cell cycle checkpoint induced by DNA damage and maintains cell 
survival [82].  Early loss of E-cadherin has been reported to contribute to sensitizing cells to 
anoikis [83].  The processes of cell attachment, survival and EMT are thus closely 
interconnected. 
  In view of the newly uncovered role of PRL-3 in cell cycle regulation, we subjected MCF7 
human breast cancer and DLD-1 colorectal cancer cells over-expressing PRL-3 or PRL-3 
(C104S) phosphatase inactive mutant to various apoptosis-inducing stresses.  We found that 
expression of PRL-3 conferred some resistance to these treatments.  We then screened the 
protein lysates of these cells for PRL-3 induced changes in tyrosine phosphorylation of various 
cell cycle related proteins, and for protein-protein interactions of PRL-3 with these proteins.  We 
found GADD34 to be a protein whose tyrosine phosphorylation was consistently up-regulated by 
PRL-3 across different cell lines, and also interacts with PRL-3.   
GADD34 is a Growth Arrest and DNA Damage inducible gene whose induction is coincident 
with onset of apoptosis in selected cell lines after exposure to ionizing irradiation or methyl 
methanesulfate (MMS) [84, 85]. GADD34 is involved in cell cycle arrest and apoptosis, as well 
as recovery from shutoff of protein synthesis induced by endoplasmic reticulum stress.  Yagi et 
al found that GADD34 induces p53 phosphorylation and enhances p21/WAF1 promoter activity 
[86].  GADD34 was shown to interact with the Src family kinase Lyn, resulting in GADD34 
phosphorylation and negative regulation of genotoxic apoptosis [85].  In this study, we found 
that PRL-3 is able to down-regulate Lyn.  This might indicate that PRL-3 is promoting GADD34 
phosphorylation in an alternative Lyn-independent manner. 
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Chapter 2:  Materials and Methods 
Construction of pSTAR-Myc-PRL-3 and pSTAR-β-galactosidase plasmids 
PCR fragments of Myc-PRL-3 and β-galactosidase were inserted into EcoRI and BamHI sites of 
the pSTAR vector [54]. 
Generation of HeLa cells transiently expressing pSTAR-Myc-PRL-3 
HeLa cells from the American Type Culture Collection (ATCC; Manassas, VA) were transiently 
transfected with pSTAR-Myc-PRL-3 [54], cultured and selected in RPMI 1640 in 1mg/ml G418 
for 24 to 48 hours before analysis. 
Confocal microscopy 
The detailed protocol was described previously [45].  The sources of antibodies are as follows:  
mouse anti-c-Myc antibody 9E10 was from Santa Cruz Biotechnology (Santa Cruz, CA); mouse 
anti-paxillin and anti-vinculin were from Transduction Laboratory (San Jose, CA); rabbit anti-
paxillin pY31 was obtained from Chemicon (Temecula, CA); or TRITC-conjugated Phalloidin 
was from Molecular Probes (Carlsbad, CA); mouse anti-PRL-3 was generated as previously 
described [45].  Confocal imaging was done using Zeiss LSM 510 image browser. 
Generation of DLD-1 human colorectal and MCF7 human breast cell pools stably 
expressing EGFP-human PRL-3 and EGFP-human PRL-3 (C104S) 
Human PRL-3 EST clone was used as PCR template for expression of human PRL-3 NH2-
terminally tagged with enhanced green fluorescent protein (EGFP-PRL-3): hR3-5’ (5’-
gtgaattctatggctcggatgaaccgcccg-3’) and hR3-3’ (5’-ctggatccctacataacgcagcaccggg-3’) were used 
to retrieve the human PRL-3 coding region by PCR.  To construct pEGFP-PRL-3 (C104S), hR3-
mid-3’ (5’- caggcccgccacggagtgcacagc-3’) and hR3-mid-5’ (5’-gctgtgcactccgtggcgggcctg-3’) 
were used with similar strategies [54] to make catalytic PRL-3 (C104S).  The PRL-3 or mutant 
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PRL-3 PCR fragment was, respectively, inserted into the EcoRI and BamHI sites of pEGFP-C1 
vector, and the respective plasmid was transfected into DLD-1 colon carcinoma cells from 
ATCC CCL-221 using LipofectAMINE 2000 from Invitrogen (Carlsbad, CA).  Generation of 
MCF7 cells expressing the same were also done in a similar manner. 
Western blot analysis 
The concentrations of the protein lysates were quantified by comparing with sequentially diluted 
commercial biovine serum albumin (10mg/ml) using Quick Start Bradford 1x Dye Reagent from 
Bio-Rad Laboratories (Hercules, CA).  Equal amount of lysate was loaded onto SDS-PAGE gel 
and resolved by electrophoresis.  The proteins were blotted onto a nitrocellulose membrane, 
which was first blocked with 5% skim milk in PBS/0.1% Tween 20 and probed with the 
appropriate antibodies.  The secondary anti-mouse or anti-rabbit horseradish peroxidase (1:1000 
dilutions) was used.  The specific binding was detected using SuperSignal West Pico 
chemiluminescence substrate (Pierce).  The following antibodies were from Cell Signaling 
Technology (Beverly, MA):  phosphorylated Akt (Ser473), Akt, phosphorylated glycogen 
synthase kinase-3β (GSK-3β; Ser9), GSK-3β, phosphorylated PTEN (Ser380/ Thr382/383), PTEN, 
E-cadherin, γ-catenin, integrin β3 and Lyn.  Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was from Chemicon (Temecula, CA).  Snail antibody was from AVIVA Systems 
Biology (San Diego, CA).   Anti-fibronectin antibody was from BD (San Jose, CA).  PI3K 
Inhibitor LY294002 from Cell Signaling Technology was used at 20 to 50 μmol/L to treat cells 






RhoA and Rac1 activity assay 
The coding sequences for the Rho-binding domain of Rhotekin (amino acids 7-89) and Rac-
binding domain of PAK (amino acids 23-137) were PCR amplified and cloned into the 
pGEX4T1 vector to create pGST-RBD and pGST-PBD, respectively.  The GST-RBD and GST-
PBD fusion proteins were purified with glutathione-sepharose beads.  Activated RhoA or 
activated Rac1 pull-down assays were done as described elsewhere [87]. 
Cell culture and treatment with apoptotic stimuli 
DLD-1 cells were cultured in RPMI 1640 with 10% foetal bovine serum.  MCF7 cells were 
cultured in RPMI 1640 with 10% foetal bovine serum, 1% non-essential amino acids and 1% L-
glutamine from Invitrogen (Carlsbad, CA).   
Annexin V-Cy5 Apoptosis Assay 
Soon after initiating apoptosis, cells translocate their membrane phosphatidylserine (PS) from the 
inner face of the plasma membrane to the cell surface, thus exposing PS to the external surface of 
the cell.  PS  on the cell surface is thus a marker of early apoptosis and can be detected by 
staining with a fluorescent conjugate of Annexin V, a Ca2+ dependent phospholipid-binding 
protein that has high affinity for PS [88-90].  In this case, the fluorescent conjugate used was 
Cy5.  We are then able to detect the staining via flow cytometry. 
3 x 106 cells were plated in 10cm tissue culture dishes about 20 hours before treatment.  They 
were treated with 1µM doxorubicin from Sigma-Aldrich (St. Louis, MO), 500µM H2O2 from 
Merck KGaA (Darmstadt, Germany) or 50µg/mL MMS from Sigma-Aldrich for 24 hours.  Cells 
were trypsinized and spun down with the culture media.  The pellet was resuspended in 1X 
Annexin V Binding Buffer from the Annexin V-Cy5 Apoptosis Detection Kit from Biovision 
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(Mountain View, CA).  The cells were then stained with Annexin V-Cy5 from the same kit for 5 
minutes at room temperature, according to manufacturer’s recommendation.  They were then 
strained before analysis using BD FACSCalibur (San Jose, CA).  The GFP expression of cells 
was detected at Ex = 488nm; Em = 509nm (FL-1; X-axis) and Cy5 was detected at Ex = 649nm; 
Em = 670nm (FL-4; Y-axis). 
Hypromatrix Cell Cycle Antibody Array screening for protein tyrosine phosphorylation 
Cells were harvested at 80% confluence and at 18-20 hours from previous splitting.  Cells were 
lysed with lysis buffer [1% Triton X-100, 150mM NaCl, 10mM Tris (pH 7.4), 1mM 
phenylmethylsulfonylfluoride (PMSF) and 0.5% NP40 with Complete Protease Inhibitor 
Cocktail from Roche Diagnostics GmBH (Mannheim. Germany)].   
The Antibody Array membranes from Hypromatrix (Worcester, MA) were used for screening 60 
different cell cycle related proteins. The Arrays contain antibodies against each of the proteins 
immobilised on a membrane, each at a predetermined position, according to the map in Table 1.  
The arrays can be used for several applications.  The first being examining protein expression 
profiles, second to study protein post translational modifications, such as protein tyrosine or 
serine/threonine phosphorylation and the third to screen protein-protein interactions.  Figure 1 
shows the principle behind the arrays.  The arrays are incubated with total protein lysates and the 
immobilised antibodies will capture their respective antigens and the antigen-interacting 
proteins.  To detect protein tyrosine phosphorylation, we then incubated the arrays with HRP 
conjugated anti-phosphotyrosine antibody, thus allowing us to visualise by ECL the tyrosine 
phosphorylation profile of the proteins captured on the array.  Using a HRP conjugated antibody 
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eliminates the need for a secondary mouse or rabbit-HRP antibody incubation as this would also 
react with the immobilised antibodies on the array. 
The arrays were pre-blocked in blocking buffer (5% skim milk in PBS-0.1% Tween 20) 
overnight at 4°C with slow shaking.  The membranes were then incubated with 500ug of protein 
lysate diluted with 1% skim milk in lysis buffer for 2 hours at room temperature with slow 
shaking.  The membranes were washed 3 times 15 minutes each with washing buffer (PBS-0.1% 
Tween 20).  The membranes were then incubated with horseradish peroxidise (HRP) conjugated 
anti-phosphotyrosine antibody (Hypromatrix) at 1:1000 dilution in blocking buffer for 2 hours at 
room temperature with slow shaking.  Washing step was repeated.  SuperSignal West Pico 
Chemiluminescent Substrate from Pierce (Rockford, IL) was applied to the arrays and then 
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Figure from www.hypromatrix.com 
Immunoprecipitation 
Cells were grown to 80% confluence and harvested at 18-20 hours from previous splitting.  Cells 
were lysed with immunoprecipitation (IP) buffer [1% Triton X-100, 150mM NaCl, 10mM Tris 
Figure 1 
Step A.  Cellular proteins are 
extracted, including phosphorylated 
proteins represented in red 
Step B.  Antibody Array is blocked 
and made available 
Step C.  Apply protein extract onto 
the array; proteins are captured by 
antibodies 
Step D.  Add HRP conjugated anti-
phosphotyrosine antibody 
Step E.  Anti-phosphotyrosine 
reacts with phosphorylated proteins 
Step F.  Phosphorylated proteins 





(pH 7.4), 1mM phenylmethylsulfonylfluoride (PMSF) and 0.5% NP40 with Complete Protease 
Inhibitor Cocktail from Roche Diagnostics GmBH (Mannheim. Germany)].  800 µg of total 
protein lysates was diluted to 2.0 µg/µl concentration in IP buffer. 5ug of anti-Phosphtyrosine 
clone 4G10 from Millipore (Termecula, CA) was added. The mixture was incubated overnight at 
4°C overnight with gentle rotation.  Protein G Sepharose beads from Amersham Biosciences 
(Piscataway, NJ) were washed several times with cold PBS and diluted 1:1 with cold PBS.  40ul 
bead volume was added to the protein lysates-antibody mixture and incubated for 5 hours at 4°C 
with gentle rotation.  The beads were then spun down at washed 2 times with cold IP buffer and 
1 time with cold PBS.  The supernatant was removed and the beads were boiled for 5 minutes in 
1x loading buffer [50uM Tris pH 6.8, 2% Sodium Dodecyl Sulphate (SDS), 10% glycerol and 
0.1% bromophenol blue] to elute proteins.  The immunoprecipitates were resolved via SDS-
PAGE and transferred to nitrocellulose membranes.  After blocking, filters were probed with 
rabbit polyclonal GADD34 (H-193) from Santa Cruz Biotechnology (Santa Cruz, CA) to assess 
tyrosine phosphorylated GADD34 by chemiluminescence.  GAPDH antibody was from 
Chemicon (Temecula, CA). 
Hypromatrix Cell Cycle Antibody Array screening for protein-protein interactions 
Hypromatrix Cell Cycle Antibody Arrays were used in a similar protocol as for protein tyrosine 
phosphorylation detection (Figure 1), but using HRP conjugated anti-GFP antibody 
(Hypromatrix) as the final incubation step instead, to detect protein-protein interactions.  The 





Principle behind detection of protein-protein interaction with the Hypromatrix Cell Cycle 
Antibody Array™ 
 
Figure from www.hypromatrix.com 
Immunoprecipitation 
Procedure was as described in previously, using 20ug of PRL-3 antibody clone 318 ascetic fluid 
[45] for pull down.  Western blot was carried out with GADD34 antibody (Santa Cruz) to detect 
GADD34 bound to PRL-3.  GFP-PRL-3 was detected with polyclonal GFP antibody Full-Length 
A.v. Polyclonal from Clontech (Mountain View, CA). 
 
Figure 2 
Step I.  Extract proteins and protein 
complexes 
Step II.   Antibody Array is blocked and 
made available. 
Step III. Apply protein extract onto Antibody 
Array.  Proteins are captured by their 
respective antibodies 
Step IV. Add HRP conjugated antibody 
against protein of interest, or appropriate tag 
(GFP) 
Step V. Antibody reacts with protein of 
interest (represented in red) 
Step VI. The interacting partner can be 
identified by its position on the array.   
   
33 
 
Reverse Transcriptase-Polymerase Chain Reaction 
RNeasy Mini Kit from Qiagen (Hilden, Germany) was used to extract total RNA from MCF7, 
MCF7-PRL-3 and MCF7-PRL-3(C104S) cells.  Cells were grown to 80% confluence and 
harvested by trypsinization.  They were spun down and the cell pellet was resuspended in Buffer 
RLT from the kit.  Total RNA was extracted according to the spin protocol recommended by the 
manufacturer.  cDNA was generated from total RNA by using SuperScript II Reverse 
Transcriptase (Invitrogen).  Qiagen HotStarTaq Master Mix was used to carry out the RT-PCR 
using the following primers – Lyn-forward (5’-gtgctggaaagaaaaggcag-3’); Lyn-reverse (5’-
tgcaactgagtggagaatcc-3’); PRL-3-forward (5’-tacaaacacatgcgcttcctc-3’); PRL-3-reverse (5’-













Chapter 3. Results and Discussion 
3.1  PRL-3 Promotes Epithelial-Mesenchymal Transition 
3.1.1 PRL-3 Reduces Paxillin, Phosphorylated Paxillin-Tyr31 and Vinculin Adhesion Molecules 
 
 
Figure 3A.  Hela cells transiently expressing EGFP-PRL-3 (HeLa-PRL-3, a and d) were labelled 
with rabbit anti-paxillin antibody and then anti-rabbit IgG conjugated with Texas Red (b and e).  
White arrows, HeLa-PRL-3 cells.  Red arrows, untransfected HeLa cells as internal control.  
Bar, 20µm. (*Contributed by Doctor Dong Jing Ming).  Figure 3B.  CHO-β-gal cells (a-c) or 
CHO- PRL-3 cells (d-f) were labelled for paxillin (a and d), phosphorylated paxillin (Tyr31; b 
and e) and vinculin (c and f) at focal adhesion complexes.  Bar, 20µm. (*Contributed by Doctor 
Dong Jing Ming)  Figure 3C.  Lysates prepared from CHO-β-gal, CHO-PRL-3, DLD-1-PRL-3 
(C104S) and DLD-1-PRL-3 cells were examined for the total levels of these adhesion proteins as 
indicated. (*Contributed by Dr Wang Haihe) 
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  The cytoskeleton is a dynamic structure that is involved in cellular migration, maintenance of 
cell shape, intracellular transport, cellular division and signal transduction.  Paxillin is a 
cytoskeletal protein associated with focal adhesions, and is involved in FAK and Src mediated 
signalling [91].  Paxillin binds vinculin, a protein that links the actin cytoskeleton to focal 
adhesions.  
  Here we found HeLa cells transiently expressing EGFP-PRL-3 showed reduced paxillin 
staining at focal adhesion complexes (Fig 3A, b and e, white arrows) compared to untransfected 
HeLa cells (red arrows).  CHO cells stably expressing myc-PRL-3 (CHO-PRL-3) also showed 
reduced staining of paxillin and phosphorylated paxillin-Tyr31 (Fig 3B, d and e).  
Phosphorylation of paxillin is stimulated by integrin-dependent adhesion to the ECM, thus a 
reduction in the tyrosine phophorylation might indicate reduced adhesion and downstream 
signalling.  We also found over-expression of PRL-3 reduced the levels of vinculin in focal 
adhesion complexes (Fig 3B, f) compared to control CHO cells expressing β-gal (Fig 3B, a-c).  
To further substantiate these immunofluorescence data, we studied the total cellular levels of 
these molecules by Western blot analysis (Fig 3C) and also found a decrease in these molecules.  













Figure 4A.  Using CHO-β-gal cells as a negative control (a), CHO-PRL-3 showed reduced 
levels of F-actin (b) as revealed by indirect immunoflourescence staining with Phalloidin.  Bar, 
20µm. (*Contributed by Assoc Professor Zeng Qi).  Figure 4B.  Cell lysates prepared from 
CHO-β-gal (lane 1), CHO-PRL-3 (lane 2), DLD-1-PRL-3 (C104S; lane 3), and DLD-1-PRL-3 
(lane 4) cells were examined for the levels of RhoA-GTP, total RhoA, Rac1-GTP, and total Rac1 
by immunoblot.  The levels of PRL-3 were also assessed, whereas glyceraldehydes-3-phosphoate 
dehydrogenase (GAPDH) was used as a loading control. (*Contributed by Doctor Wang Haihe)  
Figure 4C.  Using PRL-3 monoclonal antibody, PRL-3 was detected in membrane protrusions in 
some motile cells (a).  To-pro-3 iodide was used to stain DNA (b).  Bar, 20µm.  (*Contributed 




  Cell movement is a dynamic process that involves the coordinated assembly and disassembly of 
actin filaments.  Filamentous-actin (F-actin) is a major cytoskeleton component.  Rho GTPases 
RhoA, Rac1 and Cdc42 integrate signals from membrane receptors to the actin cytoskeleton and 
integrin adhesion complexes [92, 93]. 
  Under immunofluorescence microscopy, we found that PRL-3 reduced levels of F-actin bundles 
in CHO-PRL-3 cells (Fig 4A, b) compared to control CHO-β-gal cells (Fig 4A, a).  This 
decrease in F-actin is indicative of a destabilised cytoskeleton and increased cell migration [73].  
PRL-3 also down-regulated levels of RhoA-GTP and Rac1-GTP in both CHO-PRL-3 and DLD-
1 PRL-3 cells (Fig 4B, lanes 2 and 4) compared to controls (Fig 4B, lanes 1 and 2).   A decrease 
in activated RhoA and Rac1 leads to reduced adherens junction assembly [73, 93].  RhoA has 
been reported to increase levels of vinculin in focal adhesions in Madin-Darby canine kidney 
(MDCK) cells [94], which might account for our observations in Figure 1 of decreased vinculin 
at focal adhesion complexes.  Decreased Rac1 activity switches cell migration patterns from 
random to rapid directional migration [95], which might be the mechanism by which PRL-3 
promotes migration [54].  Cell migration requires actin-dependent protrusions at the leading 
edge.  We found that in some motile cells, PRL-3 accumulated in the structures of membrane 









3.1.3 PRL-3 Signals Through PI3K to Promote EMT 
 
  
Figure 5A. Lysates derived from DLD-1 parental cells (lane 1), DLD-1-PRL-3 (C104S) cells 
(lane 2), DLD-1-PRL-3 cells (lane 3), and DLD-1-PRL-3 cells pretreated with the PI3K inhibitor 
LY294002 (lane 4) were analysed by immunoblot to detect phosphorylated Akt (p-Akt) and total 
Akt. Figure 5B.  The same samples in (A) were first assessed for phosphorylated GSK-3β (p-
GSK-3β) and then reprobed for total GSK-3β expression levels.  Figure 5C.  The epithelial 
markers E-cadherin, γ-catenin, and integrin β3 were assessed by Western blot.  Figure 5D.  The 
mesenchymal markers fibronectin and Snail were examined by Western blot.  Glyceraldehyde-3-




 PRL-3 has so far been shown to increase motility and reduce focal adhesions, which connect the 
cytoskeleton of the cell to the ECM.  These changes are reminiscent of the process of EMT, 
which is important for embryonic development, tissue remodelling and cancer progression. 
  Here we used the human DLD-1 colorectal cancer cell line stably expressing EGFP-PRL-3 or 
phosphatase inactive mutant EGFP-PRL-3 (C104S).  The cells expressing EGFP-PRL-3 
demonstrated enhanced motility compared to those expressing EGFP-PRL-3 (C104S) (data not 
shown).  We used these cells together with parental DLD-1 cells to study possible roles for PRL-
3 in EMT.  The PI3K/Akt pathway is a central pathway in cell cycle proliferation, by regulating 
cell cycle progression as well as apoptosis.  Akt phosphorylates and inhibits GSK-3β, which  
prevents GSK-3β from phosphorylating the transcription factor Snail and targeting Snail for 
ubiquitination and proteosomal degradation [96]. Snail is a transcription factor that promotes 
EMT by repressing transcription of E-cadherin [97]. 
PRL-3 but not PRL-3 (C104S) activated Akt by phosphorylation on Ser473 (Fig 5A, lane 3), 
which results in inactivation of GSK-3β by phosphorylation at Ser9 (Fig 5B, lane 3).  This is 
followed by down-regulation of epithelial markers E-cadherin, γ-catenin (plankoglobin) and 
integrin β3 (Fig 5C, lane 3).  PRL-3 also enhanced expression of mesenchymal markers 
fibronectin and Snail (Fig 5D, lane 3).  Up-regulation of Snail could account for the repression of 
E-cadherin. 
  Activation of Akt depends on generation of the second messenger lipid phosphatidylinsoitol 
(3,4,5) triphosphate (PIP3) from phosphatidylinositol (4,5) bisphosphate (PIP2) by PI3K.  We 
postulated that PRL-3 might activate Akt through PI3K.  DLD-1 cells expressing PRL-3 were 
treated with the PI3K inhibitor LY294002 (20μmol/L). The effects of PRL-3 on Akt, GSK-3β, 
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E-cadherin, γ-catenin, integrin β3, fibronectin and Snail were all blocked by PI3K inhibition (Fig 























Figure 6A.  Lysates derived from DLD-1 cells (lane 1), DLD-PRL-3 (C104S) cells (lane 2), 
DLD-1-PRl-3 cells (lane 3), and DLD-1-PRL-3 cells pretreated with the PI3K inhibitor 
LY294002 (lane 4) were analysed by immunoblot to detect levels of phosphorylated PTEN (p-
PTEN) and total PTEN. (*Contributed by Doctor Wang Haihe).  Figure 6B.  A proposed role for 
PRL-3 in the EMT pathway.  PRL-3 acts as an upstream regulator of the PTEN-PI3K signalling 
network to evoke the cascades of EMT.  GSK, GSK-3β; E-cad, E-cadherin; γ-Cat, γ-catenin; In-
β3, integrin β3. (*Contributed by Assoc Professor Zeng Qi). 
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  To investigate how PRL-3 could activate the PI3K/Akt pathway, we also considered PTEN, 
which is an important negative regulator or PI3K action.  It antagonises PI3K by 
dephosphorylating PIP3 back to PIP2 [98]. 
  DLD-1 cells stably expressing PRL-3 or PRL-3 (C104S) were examined for PTEN levels.  
PRL-3 but not the inactive mutant PRL-3 (C104S) down-regulated phosphorylated PTEN and 
total PTEN levels (Fig 6A, lane 3).  This down-regulation would indirectly enhance Akt 
activation by removing PTEN suppression of PIP3 accumulation, facilitating tumour formation 
and metastasis.  LY294002 does not inhibit this effect (Fig 6A, lane 4), indicating that this effect 
on PTEN is not PI3K dependent.  Reverse transcription-PCR showed that mRNA levels of 
PTEN were unchanged (data not shown), implying that down-regulation of PTEN is a 
posttranscriptional event.  One possible mechanism for this reduction might be that the loss of 
vinculin-containing cell adhesions suppresses PTEN levels [99].  Another possible mechanism 
could be through decreased RhoA-GTP.  Rho-family GTPases regulate the activity of PI3K and 
PTEN, by contributing to the gradient of PIP3 for cell polarisation [100].  Active RhoA 
stimulates the phosphatase activity of PTEN by phosphorylation through its effector kinase 
ROCK [101].  The reduction of active RhoA by PRL-3 may contribute to the overall down-
regulation of PTEN activity and consequent increase in PIP3 accumulation and activation of Akt. 
  In summary, our data allows us to piece together a proposed mechanism by which PRL-3 
promotes EMT (Figure 6B).  PRL-3 operates through activation of Akt through PI3K, and by 
suppression of PTEN.  This results in inhibition of GSK-3β, allowing Snail to escape 
degradation [97].  Up-regulation of Snail together with other transcriptional events, potentially 
leads to down-regulation of epithelial markers, indicating EMT.  We suggest that PRL-3 is able 
to play a role in inducing EMT, to transform cells and drive cancer metastasis. 
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Chapter 3.2 PRL-3 Confers Resistance to Apoptosis and Up-Regulates GADD34 
Phosphorylation 
 
3.2.1 PRL-3 Confers Resistance to Apoptosis 
                         MCF7-PRL-3 (C104S)                   MCF7-PRL-3 
           
 
        
 









7.86% 18.20% 19.28% 36.65% 





31.49% 42.45% 15.27% 28.80% 
22.13% 58.40% 10.32% 43.58% 
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Figure 7A. MCF7 human breast cancer cells were subjected to treatment with 500 µM H2O2 (c 
and d) or 1µM Doxorubicin (e and f) for 24 hours.  Control cells were left untreated (a and b).  
The upper quadrants represent cells that stained positive for Annexin V-Cy5 (FL-4; Y-axis) and 
were undergoing apoptosis.  The lower quadrants represent non-apoptotic cells that were 
negative for Annexin V-Cy5 staining.  The right quadrants represent cells that are positive for 
EGFP (GFP-PRL-3 or GFP-PRL-3 (C104S)) (FL-1; X-axis), and the left quadrants represent 
cells that are negative for EGFP (untransfected MCF7 cells).  Cells transfected with GFP-PRL-3 
showed a greater proportion of viable non-apoptotic cells (lower right quadrant) compared to 
GFP-PRL-3 (C104S) transfected cells under control and both treatment conditions.  Control 
conditions:  40.95% (b) vs 28.17% (a), H2O2 treatment: 36.65% (d) vs 18.20% (c), Doxorubicin 












                DLD-1-GFP-PRL-3 (C104S)            DLD-1-GFP-PRL-3 
   
 
       
 























Figure 7B. DLD-1 human colorectal cancer cells were subjected to treatment with 500µM H2O2 
(c and d) or 50µg/mL MMS (e and f) for 24 hours.  Control cells were left untreated (a and b).  
Cells transfected with GFP-PRL-3 showed a greater proportion of viable non-apoptotic cells 
(lower right quadrant) compared to GFP-PRL-3 (C104S) transfected cells under control and both 
treatment conditions.  Control conditions: 46.78% (b) vs 35.11% (a), H2O2 treatment:  46.68% 
(d) vs 23.82% (c), MMS treatment: 57.07% (f) vs 33.36% (e). 
 
  Evading programmed cell death enables transformed cells to survive detachment from 
neighbouring cells or ECM and acquire anchorage independent growth.  Cancer cells can take 
advantage of this property to colonise new tissues.  Programmed cell death can also be triggered 
by oxidative stress and DNA damage.  Hydrogen peroxide (H2O2) is a Reactive Oxygen Species 
(ROS) that induces oxidative injury to cells and is a secondary messenger in signal transduction.  
Doxorubicin is a commonly used drug to treat breast cancer.  It is able to intercalate DNA, 
inhibit macromolecular biosynthesis and interfere with DNA unwinding [102].  MMS is an 
alkylating agent that causes DNA fragmentation and stalled replication forks [103].  Exposure to 
these agents triggers cells to undergo apoptosis. 
  MCF7 cells transfected with PRL-3 or PRL-3 (C104S) mutant were subjected to H2O2 and 
Doxorubicin treatment.  Analysis by flow cytometry showed that the population of transfected 
cells that were non-apoptotic was higher in PRL-3 transfected cells compared to PRL-3 (C104S) 
transfected cells.  After treatment with H2O2, the population of transfected cells (upper and lower 
right quadrants) that were non-apoptotic (lower right quadrant) was 56.00% in PRL-3 expressing 
cells compared to 30.01% in PRL-3 (C104S) expressing cells.  After Doxorubicin treatment, the 
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population of transfected cells that were non-apoptotic was 43.27% in PRL-3 expressing cells 
compared to 14.97% in PRL-3 (C104S) expressing cells.  Similarly, DLD-1 cells transfected 
with PRL-3 or PRL-3 (C104S) mutant were subjected to H2O2 and MMS treatment.  After H2O2 
treatment, 56.51% of PRL-3 transfected cells were non-apoptotic compared to 35.33% of PRL-3 
(C104S) transfected cells.  After MMS treatment, 60.26% of PRL-3 transfected cells were non-
apoptotic compared to 46.30% of PRL-3 (C104S) transfected cells. 
These results give us a hint at the potential of PRL-3 to promote cell survival and resistance to 
apoptosis triggered by DNA damage and oxidative stress.  This could drive survival of cells with 

















Figure 8A-C. Hypromatrix Cell Cycle Antibody Array™ used to screen tyrosine phosphorylation 
profiles.  The profiles of three sets of cell lines were examined - DLD-1 human colorectal cancer (a), 
MCF7 human breast cancer (b) and Chinese Hamster Ovary (CHO) cells (c) expressing either GFP-PRL-
3 or GFP-PRL-3 (C104S) phosphatase inactive mutant.  GADD34 (Position A3, circled in red) was 
consistently up-regulated between all three sets of cells, indicating that PRL-3’s phosphatase activity 




Figure 8D and 8E. Immunoprecipitation with anti-phosphotyrosine (pY) clone 4G10 antibody 
to detect tyrosine phosphorylated GADD34.  GADD34 is more highly phosphorylated in both 
MCF7 (a) and DLD-1 (b) cells expressing PRL-3 (lane 3) compared to control (lane 1) or PRL-3 










  Over-expression of PRL-1 and PRL-2 has been found to enhance G1 to S phase cell cycle 
progression through down-regulation of p21Cip1/Waf1 levels [80].  PRL-3 has recently been 
reported to be a p53 inducible gene that regulates cell cycle progression in a dose-dependent 
manner [78]. Our previous findings (Chapter 3.1 and [57]) revealed that PRL-3 promotes 
activation of AKT and down-regulation of PTEN.  Besides EMT, this also enables cells to 
overcome G2/M cell cycle checkpoint induced by DNA damage [82].   
To find other potential cell cycle regulators PRL-3 might act on, we screened an array of cell 
cycle related proteins to find those whose tyrosine phosphorylation status is affected by over-
expression of PRL-3. 
  The Hypromatrix Cell Cycle Antibody Array allows screening for changes in protein tyrosine 
phosphorylation of 60 different cell cycle related proteins in whole cell protein lysates.  The 
arrangement of the array is depicted in Table 1.  Antibodies against the proteins are immobilised 
on the membrane.  They capture their respective antigens from the protein lysates and HRP 
conjugated anti-phosphotyrosine antibody detects the tyrosine phosphorylated residues on these 
captured proteins.  The principle is illustrated in Figure 2. 
  GADD34, a Growth Arrest and DNA Damage inducible gene, was found to be consistently 
upregulated in the three different cell lines, DLD-1 (Figure 8A) , MCF7 (Figure 8B) and CHO 
(Figure 8C) cells transfected with PRL-3 compared to PRL-3 (C104S) mutant.  This was further 
confirmed by immunoprecipitation (Figure 8D and 8E).  Whole cell lysates were 
immunoprecipitated with anti-phosphotyrosine antibody (Clone 4G10).  GADD34 detected from 
the IP product would be enriched for the tyrosine phosphorylated form of GADD34.  Total 
GADD34 and GAPDH are shown here as input loading controls.  Phosphotyrosine levels in 
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lysates and immunoprecipitate are shown here to demonstrate enrichment of tyrosine 
phosphorylated proteins (75kD).  PRL-3 expressing cells (Lane 3) showed higher levels of 
tyrosine phosphorylated GADD34 compared to PRL-3 (C104S) cells (Lane 2). 
  One possible consequence of GADD34 phosphorylation is inhibition of genotoxic induced 
apoptosis [85].  Over-expression of PRL-3 could be indirectly causing phosphorylation of 



















Figure 9A-B. Hypromatrix Cell Cycle Antibody Array™ used to screen protein-protein 
interactions. GADD34 (position A3, circled in red) binds to PRL-3 more strongly than to PRL-3 
(C104S) mutant in both DLD-1 (a) and MCF7 (b) cell lines.  Figure 9C.  Immunoprecipitation 
with PRL-3 antibody to detect protein-protein interaction.  Lanes 1-3 show the lysates before 
immunoprecipitation.  GADD34 binds more strongly to MCF7 cells expressing GFP-PRL-3 




  The Hypromatrix Cell Cycle Antibody Array can also be used for detecting protein-protein 
interaction. We screened protein lysates of DLD-1 and MCF7 cells to find proteins that interact 
with PRL-3. The antibodies fixed on the array capture their respective antigens from whole cell 
protein lysates, together with their interacting proteins.  In order to detect protein-protein 
interaction, we used HRP conjugated GFP antibody to detect GFP-PRL-3 and GFP-PRL-3 
(C104S).  GADD34 (Position A3) once again emerged as a protein of interest, being found to 
consistently bound more abundantly to PRL-3 compared to mutant PRL-3 (C104S) in both DLD-
1 (Figure 8A) and MCF7 (Figure 9B) cells.  The MCF7 results were further confirmed by 
immunoprecipitation (Figure 9C).  Whole cell lysates were immunoprecipitated with PRL-3 
antibody (Clone #318).  GFP-PRL-3 is shown here as a loading control and to demonstrate the 
efficiency of the pull-down.  Consistent with the antibody array results, GADD34 binds more 
strongly to PRL-3 (Lane 3) compared to PRL-3 (C104S) (Lane 2). 
  The interaction between GADD34 and PRL-3 might possibly result in some conformational 
change in GADD34 to enable it to be more easily phosphorylated.  Another possibility is that 
this interaction creates a larger protein complex that has downstream functions.  This interaction 
is reminiscent of GADD34’s interaction with the catalytic subunit of Protein Phosphatase 1 
(PP1), which results in dephosphorylation of eIF2α [104].  GADD34 also binds other proteins 
that are known modulators of protein phosphatase activity [105].  Here GADD34 interacts more 
strongly with catalytically active PRL-3 compared to the inactive mutant.  It is possible that 
while PRL-3 promotes phosphorylation of GADD34, GADD34 could also influence the activity 




3.2.4 PRL-3 Down-regulates Lyn 
 
 
Figure 10A. Western blot of transiently (lanes 1-3) and stably (lanes 4-6) transfected MCF7 
cells. Both sets show Lyn protein levels to be down-regulated in PRL-3 expressing cells (Lanes 3 
and 6) compared to untransfected (lane 4), GFP vector transfected (lane 1) and GFP-PRL-3 
(C104S) mutant transfected (lane 2 and 5) cells.  Figure 10B. RT-PCR to show levels of Lyn 
and PRL-3 transcript with GAPDH as a loading control.  Lyn transcripts are down-regulated in 
MCF7 cells transfected with PRL-3 (lane 3) compared with untransfected control cells (lane 1) 





  Following our finding that PRL-3 could up-regulate GADD34 tyrosine phosphorylation, we 
investigated Lyn, which is a Src Family Kinase that has been reported to interact with GADD34 
and phosphorylate it [85].  Src family kinases play an important role in coupling cell surface 
receptors to cytoplasmic signalling.  They are involved in regulation of cell adhesion and 
migration through integrin signalling [23, 24].  They are also involved in cell proliferation, 
differentiation and cell shape changes. 
  We found that PRL-3 over-expression led to down-regulation of Lyn protein in MCF7 cells.  
The protein levels of Lyn were down-regulated by PRL-3 under transient (Figure 10A, Lane 3) 
and stable expression conditions (Lane 6).  We then observed the mRNA levels of Lyn and 
found that PRL-3 down-regulated Lyn transcript as well (Figure 10B, Lane 3).  This suggests 
transcriptional down-regulation. 
  This was unexpected as we anticipated Lyn would be up-regulated, since it has been reported to 
phosphorylate GADD34 in response to DNA damage [85]. However, as our observations of 
GADD34 phosphorylation and Lyn down-regulation were in normal cell culture conditions 
where cells were not challenged with any stimulus.  We postulate that in this context, PRL-3 may 
be promoting GADD34 phosphorylation in a Lyn-independent manner. 
  The functional domain of GADD34 involved in executing apoptosis is reported to be the region 
of amino acids 1-214.  Proteins binding in this region may be involved in execution of apoptotic 
activity and proteins that bind outside this region may modulate the apoptotic activity [105].  We 
searched for possible phosphorylation sites on GADD34 using PhosphoSitePlus and found that 
GADD34 has one potential tyrosine phosphorylation site at Y262 [106].  We also searched for 
possible kinase binding motifs on GADD34 using ScanSite [106] and found that GADD34 has 
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an Erk1 Kinase binding motif (RTSTSALSPGSKPST) at S212 and a PDK1 binding site group 
(EEGVNKFSYPPSHRE) at S178.  Both these sites are close to the potential tyrosine 
phosphorylation site as well as the apoptosis execution domain.  PI3K action generates PIP3 at 
the plasma membrane, recruiting PDK1 and Akt to bind PIP3, resulting in phosphorylation of 
Akt [25].  We have previously shown PRL-3 is able to up-regulate phosphorylation of Akt [57], 
















Chapter 4. Concluding Remarks 
  Cancer metastasis is the leading cause of death in cancer patients.  Metastasis is a multi-step 
process that involves cancer cells acquiring traits that allow them to detach from the primary 
tumour, enter the blood or lymph circulation, and survive to reach a receptive microenvironment 
to colonise it [3].  Protein phosphorylation regulates many signalling pathways that regulate key 
cellular processes.  Protein kinases and phosphatases maintain the proper balance of 
phosphorylation status of signalling proteins, determining their activity.  Inappropriate kinase or 
phosphatase activity disrupts signal transduction, and can drive cells towards malignancy. 
  The PRL family is a unique family of protein tyrosine phosphatases that contain a PTP active 
site sequence and the prenylation motif CAAX [42].  The third member of the family, PRL-3, 
has been linked to metastasis since Vogelstein’s group linked its transcripts to colorectal cancer 
progression in 2001 [43].  Since then, PRL-3 has been found to be involved in many cancer-
associated cell properties, including transformation, migration, invasion, tumorigenesis and 
metastasis. 
   Here we showed PRL-3 over-expression reduces key focal adhesion molecules paxillin (total 
and phosphorylated form) and vinculin (Figure 3).  This might indicate reduced contacts between 
cells and the ECM.  PRL-3 also decreases the levels of F-actin, a key component of the 
cytoskeleton.  Levels of active RhoA and Rac1 were also reduced by PRL-3.  Additionally, PRL-
3 was found to be polarised in membrane protrusions of some motile cells (Figure 4).  Taken 
together, it seems PRL-3 destabilises the cytoskeleton, and alters key signal transducers between 
the ECM and cytoskeleton.  Changes in cell adhesion and motility are features of the process of 
Epithelial-Mesemchymal Transition (EMT).  We studied PRL-3’s effect on the PI3K/Akt 
pathway which regulates EMT, and important epithelial and mesenchymal markers.  We 
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discovered PRL-3 is able to activate the Akt via PI3K and up-regulate epithelial markers E-
cadherin, γ-catenin and integrin β3, while at the same time down-regulating mesenchymal 
markers fibronectin and snail (Figure 5).  PRL-3 further enhanced PI3K action by down-
regulating PTEN, the phosphatase responsible for reversing PI3K phosophorylation of PIP2 to 
PIP3 (Figure 6A).  We conclude that PRL-3 promotes EMT via PI3K and PTEN, activating Akt 
and finally resulting in transcriptional suppression of epithelial markers (Figure 6B). 
Cancer progression also requires overcoming cell cycle arrest and apoptosis.  The Akt pathway 
not only plays a role in EMT, it also is involved in integrin signalling to regulate detachment-
induced apoptosis [10].  Thus PRL-3 activation of PI3K/Akt might also have consequences for 
cell survival.  Akt activation also overcomes G2/M cell cycle checkpoint induced by DNA 
damage [82].  We found that PRL-3 was able to confer some degree of resistance to various 
genotoxic apoptosis-inducing stimuli (Fig 7).  We used an antibody array (Fig 1) and screened 
for cell cycle related proteins whose tyrosine phosphorylation status was affected by PRL-3, and 
found GADD34 to be of interest.  PRL-3 consistently up-regulated the phosphorylation of 
GADD34 in the three cell lines tested (Fig 8).  Phosphorylation of GADD34 results in inhibition 
of its pro-apoptotic activity in response to genotoxic damage [85].  GADD34 was also found to 
interact with PRL-3 using the same array, and confirmed this with immunoprecipitation (Fig 9).   
It is possible that binding of GADD34 and PRL-3 might render GADD34 more easily 
phosphorylated or they could be mutually regulating each other.  PRL-3 could also be activating 
a kinase responsible for phosphorylation of GADD34.  We checked if PRL-3 had any effect on 
Lyn, a Src Family Kinase known to phosphorylate GADD34 [85].  The consequence of 
GADD34 phosphorylation by Lyn is negative regulation of its proapoptotic response to DNA 
damage.  We found that PRL-3 down-regulated Lyn protein levels as well as mRNA transcript 
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levels (Fig 10).  This finding indicates that the GADD34 phosphorylation we observed might be 
brought about by an alternative pathway independent of Lyn.  We conclude that PRL-3 confers 
some resistance to DNA damaged-induced apoptosis, through GADD34 phosphorylation. 
  Here we have shown PRL-3 plays its role in metastasis and tumour progression through these 
two important processes, EMT and resistance to DNA damage induced apoptosis.  Taken 
together, cancer cells that over-express PRL-3 can transform from epithelial cells to adopt a 
more motile and invasive mesenchymal cells.  At the same time, they would be able to evade 
apoptosis to reach their new sites of colonisation.  These findings contribute to the growing body 
of evidence that PRL-3 is a multi-tasking phosphatase, involved in progression of various major 
human cancers through different cellular processes.  Thus, PRL-3 remains an attractive potential 












Claims to original discovery 
  In the course of our investigations, several findings were made which, to our knowledge, are 
novel and have not been reported previously.  These are listed below: 
1) PRL-3 reduces focal adhesion molecules paxillin, phosphorylated paxillin-Tyr31 and 
vinculin. 
2) PRL-3 decreases cytoskeletal filamentous actin. 
3) PRL-3 activates AKT in a PI3K-dependent manner and down-regulates PTEN. 
4) PRL-3 promotes Epithelial-Mesenchymal Transition, down-regulating epithelial markers 
E-cadherin, γ-catenin and integrin β3, and up-regulating mesenchymal markers 
fibronectin and snail. 
5) PRL-3 confers resistance to apoptosis induced by DNA damaging agents and H2O2. 
6) PRL-3 binds to GADD34 and up-regulates GADD34 phosphorylation 











The work in Chapter 2 was published in Cancer Research; 2007; 67: (7) 2922-2926. PRL-3 
Down-regulates PTEN Expression and Signals through PI3K to Promote Epithelial-
Mesenchymal Transition. Authors:  Haihe Wang, Samantha Yiling Quah, Jing Ming Dong, 
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